CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Incyte Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Incyte Corp
1801 Augustine Cut-Off
Phone: (302) 498-6700p:302 498-6700 WILMINGTON, DE  19803  United States Ticker: INCYINCY
Business Summary
Incyte Corporation is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of therapeutics. The Company operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise is comprised of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. The Company manages business activities on a consolidated basis through the development and commercialization of oncology and dermatology products.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 Morningstar DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Julian C.Baker 59 6/26/2025 11/26/2001
President, Global Head - Research and Development Pablo J.Cagnoni 63 3/25/2026 5/1/2023
Chief Executive Officer, Director William J.Meury 58 3/25/2026 6/26/2025
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Escient Pharmaceuticals, Inc. 10578 Science Center Drive San Diego CA United States

Business Names
Business Name
ARIAD Europe
Escient Pharmaceuticals Australia Pty Ltd
Escient Pharmaceuticals, Inc.
26 additional Business Names available in full report.

General Information
Number of Employees: 2,844 (As of 12/31/2025)
Outstanding Shares: 199,782,155 (As of 4/21/2026)
Shareholders: 97
Stock Exchange: NASD
Federal Tax Id: 943136539
Fax Number: (302) 636-5454
Email Address: webmaster@incyte.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, June 14, 2026